PT-141 peptide (Bremelanotide)
PT-141 peptide, also known as bremelanotide, is a peptide that affects signaling pathways in the brain involved in sexual arousal and desire. It was originally studied as a potential treatment for sexual dysfunction and later developed into a prescription medication for a specific medical indication.
Bremelanotide was developed by Palatin Technologies in collaboration with AMAG Pharmaceuticals and is marketed under the brand name Vyleesi.
How PT-141 peptide works
PT-141 belongs to a class of compounds known as melanocortin receptor agonists. Unlike many drugs used to treat sexual dysfunction, it does not act directly on blood vessels.
Instead, PT-141 works primarily within the central nervous system, where it activates melanocortin receptors involved in regulating sexual behavior and arousal. Its main mechanisms include:
activating melanocortin receptors (primarily MC4R) in the brain
influencing neural pathways involved in sexual desire and arousal
modulating signaling systems linked to motivation and reward
Because of its central mechanism of action, PT-141 peptide differs from medications such as Sildenafil, which primarily affect blood flow in peripheral tissues.
Clinical trials and evidence
Bremelanotide has been evaluated in multiple clinical trials investigating its effects on hypoactive sexual desire disorder (HSDD) in premenopausal women.
In large randomized clinical studies, participants receiving bremelanotide reported:
improvements in sexual desire scores
reductions in distress associated with low sexual desire
measurable differences compared with placebo in validated clinical questionnaires
Based on the results of these trials, bremelanotide received regulatory approval in the United States for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Research has also explored the peptide’s potential role in other forms of sexual dysfunction, although these applications remain less well established.
Possible side effects of PT-141 peptide:
Like any medication affecting central nervous system signaling, PT-141 may cause side effects in some individuals. Commonly reported side effects include:
nausea
flushing
headache
temporary increases in blood pressure
injection site reactions
Because the medication can affect cardiovascular parameters, healthcare providers typically evaluate whether the therapy is appropriate for a particular patient before initiating treatment.
Treatment should always be prescribed and monitored by a qualified healthcare professional.